Sign in
Taking people in ItalyPhase 1/2

Tests modified immune cells in adults with hard-to-treat autoimmune diseases

Tests a patient's own modified immune cells in adults with lupus or similar conditions.

Key facts

Who runs it
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Where
Rome, ItalySee the site
Registry title
Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases
Status
Recruiting
Phase
Phase 1/2
People taking part
8 people, planned
Started
29 Nov 2024
Planned end
Dec 2025
Type of study
Interventional
Treatments tested
  • CAR T cell
Record updated
11 April 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with severe lupus, systemic sclerosis, myositis (DM/PM) or ANCA vasculitis that did not respond to usual treatments. They would get one dose of CAR T-cell therapy.

Age
18 years or older and under 65 years.
Sex
All sexes can join.
Disease stage
Active, hard-to-treat disease. Lupus: active disease with severe or moderate organ involvement (BILAG score). Systemic sclerosis: diffuse type, disease for 5 years or less, getting worse fast. Myositis: muscle weakness. ANCA vasculitis: active disease with kidney or other organ signs.
Earlier treatment
Usual treatments did not work well enough. Lupus, systemic sclerosis and myositis: glucocorticoids plus at least 2 other listed drugs. ANCA vasculitis: at least 1 of glucocorticoids, cyclophosphamide or B-cell targeting therapy. No earlier CAR T-cell therapy.
Biomarker or test result
Disease-specific antibodies are needed: for lupus anti-dsDNA, anti-histone, anti-nucleosome or anti-Sm; for myositis at least one myositis-specific antibody; for ANCA vasculitis ANCA against proteinase 3 or myeloperoxidase. Two doses of SARS-CoV-2 vaccine, or SARS-CoV-2 infection in the last 6 months.

Main reasons for not taking part

  • Pregnant or breastfeeding women
  • Severe active infection, including HIV, active hepatitis B or C, active tuberculosis or COVID-19
  • Cancer in the last 5 years (fully removed carcinoma in situ is allowed)
  • Serious heart disease or weak kidney function (eGFR below 30 ml/min)
  • Earlier CAR T-cell therapy, or another trial drug affecting T or B cells in the last 2 years

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • General; Subjects must understand and voluntarily sign an informed consent form, including written consent for data protection; Adults aged ≥ 18 years and < 65 years at time of consent; Male subjects, unless surgically sterile, must agree to use two acceptable methods for contraception (e.g., spermicide and condom) during the trial and refrain from fathering a child starting from the time of signing the Informed Consent Form (ICF) until 12 months after dosing of the IMP; Females of childbearing potential (FCBP) must have a negative urine pregnancy test at screening and must agree to use a highly effective contraceptive method (Pearl index <1) starting from the time of signing the ICF and for 12 months after dosing of the IMP; Must be able to adhere to the study visit schedule and other protocol requirements; Double vaccination (2 doses) against SARS-CoV-2 or SARS-CoV-2 within the last 6 months
  • SLE subjects; Fulfilling the 2019 ACR/EULAR classification criteria of SLE; b) Presence of anti-dsDNA, anti-histone, anti-nucleosome or anti-Sm antibodies; c) Active disease at screening, defined as ≥1 organ system with a British Isles Lupus Assessment (BILAG) A score (severe disease activity) or ≥2 organ systems with a BILAG B score (moderate disease activity); d) Insufficient response to glucocorticoids and at least 2 of the following treatments: hydroxychloroquine, mycophenolate mofetil, belimumab, methotrexate, rituximab
  • SSc subjects; Fulfilling the 2013 ACR/EULAR classification criteria of SSc; Diffuse SSc with respective autoantibody profile; Signs for fast progression including i) disease duration ≤5 years (from onset of first non-Raynaud manifestation), ii) mRSS score 10-35 at screening, iii) elevated acute phase reactant levels (CRP ≥ 6 mg/L, ESR ≥ 28mm/h or platelet count ≥ 330 000/mm3), iii) mRSS increase ≥ 3 units or involvement of one new body area or mRSS increase ≥ 2 units in one body area or ≥1 tendon friction rub over 6 months; Insufficient response to glucocorticoids and to at least 2 of the following treatments:; mycophenolate mofetil, azathioprine, nintedanib, methotrexate, rituximab
  • DM/PM subjects; Fulfilling the 2017 ACR/EULAR classification criteria for probable or definite DM or PM57, b) Muscle weakness as defined by MMT < 142 and 2 of the following criteria: VAS patients Global ≥ 2 cm, VAS physician Global ≥ 2 cm, HAQ > 0.25, at least one muscle enzyme >1.3 times upper limit of normal, VAS global extra muscular activity ≥ 2 cm; c) Presence of at least one myositis-specific antibody; d) Insufficient response to glucocorticoids and to at least 2 of the following treatments: mycophenolate mofetil, ciclosporin A, tacrolimus, methotrexate, rituximab, and intravenous immunoglobulins
  • AAV subjects; Fulfilling the 2022 ACR/EULAR classification criteria for MPA/GPA/EGPA,; Presence of ANCA to either proteinase 3 or myeloperoxidase; At least one major or three non-major items or at least two renal items of hematuria and proteinuria on the BVAS; Failure of at least 1 of the following treatments: glucocorticoids, cyclophosphamide, or B-cell targeting therapy

Who cannot take part

  • Evidence of significant and uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results
  • Any concomitant severe active infection, including HIV (even with negative viral load), active hepatitis B (either positive for Hepatitis B core antibody [HBcAb] or positive hepatitis B surface antigen [HBsAg] and NAT tests) and/or C (<12 weeks between achievement of a sustained virological response to the specific treatment and apheresis) according to the American Association for the Study of Liver Diseases guidelines, SARS-CoV 2 (COVID 19), or active tuberculosis as defined by a positive Quantiferon TB-test. If the presence of latent tuberculosis is established, then treatment according to local guidelines must have been initiated before enrolment
  • Malignancy in the last 5 years before screening. The inclusion of patients with previously completely resected carcinoma in situ who have not required treatment other than surgery is allowed
  • Previous CAR T cell administration
  • A therapeutic schedule not compatible with the wash-out requirements for the leukapheresis procedure (section 5.8.1 of CSP) and the medications permitted during the study (section 7.11 of CSP)
  • Concurrent treatment with other investigational agents or participation in other investigational trials
  • Treatment, as part of an investigational clinical trial, with an experimental product with a definite or potential effect on T or B-cells in the previous 2 years
  • Requirement for immunization with live vaccine during the study period or within 14 days preceding leukapheresis
  • Patients with evidence on thorax CT of advanced fibrotic interstitial lung disease and whose latest pulmonary function test showed a Forced Vital Capacity (FVC) < 40% of predicted or a Diffusing Capacity for Carbon Monoxide (DLCO) < 30% of predicted
  • Known hypersensitivity to either any drug components or any auxiliary medicinal products scheduled during trial participation, including during lymphodepletion
  • Have a history of alcohol or substance abuse within the preceding 6 months that, in the opinion of the Investigator, may increase the risks associated with study participation or study agent administration or may interfere with the interpretation of results
  • Limited to patients diagnosed with SLE: patients with a history of severe central nervous system (CNS) involvement, including those who have presented aseptic meningitis, cerebral vasculitis, cerebrovascular disease, demyelinating syndrome, myelopathy, seizure disorder, status epilepticus, and severe lupus headache, will be excluded
  • Patients meeting the classification criteria for multiple connective diseases such as overlapping SLE and Sjogren's Syndrome (SS) or SLE and Rheumatoid Arthritis (RA) and patients diagnosed with Mixed Connective Tissue Disease (MCTD)
  • ANC < 1.000/mm3, ALC < 500/mm3 or hemoglobin < 8 g/dl, absolute CD3+ T cell count ≤100/µl
  • Relevant cardiovascular disease: recent history of myocardial infarction, cardiac angioplasty or stenting, unstable angina, significant arrhythmia, congestive heart failure, or left ventricular ejection fraction < 50%, as determined by echocardiography
  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
  • Impaired renal function, i.e., eGFR < 30 ml/min
  • Subjects who are younger than 18 years or are incapable of understanding the aim, importance, and consequences of the study and giving legal informed consent
  • Clinically suitability for a less burdensome and/or approved therapeutic approach, as judged by the investigator
  • Pregnant or lactating females
  • Subjects who possibly are dependent on the Sponsor, the Principal Investigator, or the Investigator (e.g., family members)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in Italy

  • Fondazione Policlinico Universitario A. Gemelli IRCCSRome, ItalyContact: Giulia WlderkTaking people

About the trial

What the trial wants to find out

The CATARSIS study explores the use of anti-CD19 CAR T-cell therapy as a novel approach for treating refractory systemic autoimmune diseases, specifically SLE, SSc, DM/PM, and AAV. These life-threatening conditions often resist current therapies, and B cells play a key role in their pathogenesis. The study employs CD19-CAR_Lenti, an autologous CAR T-cell product targeting CD19-positive B cells, aiming to reduce inflammation and autoimmunity. This open-label, single-dose, phase I basket trial will assess the safety, feasibility, and preliminary efficacy of CAR T-cell therapy, focusing on adverse events, infection rates, and overall response at 24 weeks. Eight participants will be included.

The group in the trial

  • Anti-CD19 CAR T cellTreatment being tested

    Single intravenous infusion of 1 x 106 /kg body weight CAR T cell ("CD19-CAR\_Lenti" )

    Treatment: CAR T cell

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases
Plain-language title
Tests modified immune cells in adults with hard-to-treat autoimmune diseasesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06685042, who can take part
Record updated
11 April 2025